Meet Dr. Joshua Bauml

Another amazing human.

On today's episode meet Dr. Joshua Bauml. Dr. Bauml is the Lung Cancer Disease Area Stronghold Leader at Johnson & Johnson Innovative Medicine. As the Lung Cancer DAS leader, Dr. Bauml is responsible for end-to-end Lung Cancer Development including mature assets (Rybrevant and Lazertinib) as well as identifying new assets in early development and/or partnerships.

He received his undergraduate from Tufts University, Boston and completed his residency and earned his MD at the Icahn School of Medicine at Mt. Sinai. He completed his fellowship at the University of Pennsylvania.